Trial Profile
Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bone metastases; Non-small cell lung cancer
- Focus Adverse reactions
- 02 Nov 2022 Status changed to discontinued.
- 30 Apr 2018 New trial record